ReviewVisceral medicine2022
Resection of Recurrent Pancreatic Cancer: Who Can Benefit?
Review in Visceral medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Surgical Re-Resection for Isolated Local Recurrence of Pancreatic Cancer: A Case Series of 3 Patients and Literature Review.Acta medica academica · 2026Review
- Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine.Frontiers in medicine · 2026Article
- Unraveling the molecular landscape of pancreatic cancer: a systems biology approach to identify therapeutic targets.Discover oncology · 2025Article
- mRNA-Based Neoantigen Vaccines in Pancreatic Ductal Adenocarcinoma (PDAC)-A Promising Avenue in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- Pancreatectomy with arterial resection following neoadjuvant FOLFIRINOX: A single-institution experience.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights.World journal of clinical oncology · 2025Review
- Calliviminone A fromPlants (Basel, Switzerland) · 2025Article
- Contrast-enhanced photon-counting detector CT for discriminating local recurrence from postoperative changes after resection of pancreatic ductal adenocarcinoma.European radiology experimental · 2025Article
- Plasma treatment can efficiently increase the attachment of pancreatic circulatory tumor cells to the surface.Discover oncology · 2025Article
- Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery.Scientific reports · 2024Article
- Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.Current oncology (Toronto, Ont.) · 2024Review
- Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.Radiation oncology (London, England) · 2024Article
- Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma.Cancers · 2023Review
- Editorial: Multimodality Treatment in Pancreatic Ductal Adenocarcinoma - Current Options and the Future Impact of Molecular Biological Profiling.Visceral medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrence after resection of pancreatic cancer occurs in up to 80% of patients in the first 2 years after complete resection. While most patients are not eligible for surgical treatment due to disseminated disease, a certain group of patients can be evaluated for re-resection of local recurrence. This review summarizes the current literature on surgical treatment of recurrent pancreatic cancer and potential prognostic factors. Summary: Re-resection of recurrent pancreatic cancer provides a significant survival benefit to selected patients with acceptable procedure-related mortality. Median overall survival after re-resection of recurrent pancreatic cancer is up to 28 months. The most relevant clinical parameters associated with a prognostic benefit are young patient age (<65 years), time to initial resection (>10 months), and preoperative chemotherapy before re-resection. Molecular markers are currently under investigation and might help to improve patient selection in the future. Key Message: Re-resection of recurrent pancreatic cancer is safe and feasible in experienced hands. Selected patients benefit from surgical treatment, but future studies are needed to identify reliable prognostic markers predicting survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.